Skip Ribbon Commands
Skip to main content
Menu

Peptide receptor radionuclide therapy (PRRT)

Peptide receptor radionuclide therapy (PRRT) - What it is

​Peptide receptor radionuclide therapy is a type of radiopharmaceutical therapy which is given to patients through an intravenous infusion. This treatment is prescribed for patients who have advanced neuroendocrine tumours. Neuroendocrine tumours are sensitive to radiation and commonly overexpress certain types of somatostatin receptors. A radioactive material is bound to a drug which targets these receptors – this is called a radiolabelled peptide. The radiolabelled peptide is taken into the tumour cells, where radiation can exert its effects. The radionuclide used in this therapy is usually Lutetium 177 (Lu-177).

Peptide receptor radionuclide therapy (PRRT) - How to prevent?

Peptide receptor radionuclide therapy (PRRT) - Causes and Risk Factors

Peptide receptor radionuclide therapy (PRRT) - Treatments

Peptide receptor radionuclide therapy (PRRT) - Other Information

The information provided is not intended as medical advice. Terms of use. Information provided by SingHealth

TOP
Discover articles,videos, and guides afrom Singhealth's resources across the web. These information are collated, making healthy living much easier for everyone.